+ Watch NBS
on My Watchlist
No, I haven't suddenyl fallen head over heels with a stem cell stock. I still believe none of these highly self-promotional companies have done anything to prove they are legitimate enterprises. This is a short term bet that Neostem will rise ahead of topline data from PReSERVE currently expected in the second half of this year. The stock has fallen below the recent trading range but I don't think this is a sustained decline due to biotech sector weakness or the latest stem call failure from Athersys. I don't have a great record with these hold-my-nose green thumbs, so if I end up having to hold through data this could be my latest embarrassing plunge.
trade buy@ 6.8 TP 8
stem cell research is wave of the future. the future is now!
NBS has a novel therapy using stem cells that may become the standard of the cardio-health industry. This is a small company with lots of potential and multiple irons in the fire.
i think in time
NBS has 4 business units- each of which could easily be a company in its own right. They are at the forefront of a new paradigm in treating certain diseases. The current money-maker is Progenitor Cell Therapy (PCT) which is the manufacturing unit using proprietary technology to manufacture stem cells for other pharma companies. This allows NBS to make money while developing their own stem cell therapies. And perfect their manufacturing techniques. The best known unit is Amorcyte due to phase 2 clinical trial of AMR-001 (autologous marrow stem cells f) for acute myocardial infarction. The Athelos unit is developing the lesser know human regulatory T cell therapy approach (patented technology) to immune-mediated diseases (ie, asthma or type 1 diabetes). This Treg technology has been licensed out to other companies, earning money for the development of this novel therapeutic approach. The VSEL unit is developing pluripotent stem cells (very small embryonic-like stem cells) for regenerative therapies (e.g., wounds or bone regeneration). As this is early research, VSEL is partnering with universities and government organizations to learn about these VSELs. Finally, tthrough the relationships with pharma companies developed by PCT or Athelos, NBS could potentially negotiate a favorable development agreement with a larger company to fund clinical development through phase 3 and approval. This approach has worked for other small biotech companies in recent years. As a forerunner in this new field, NBS could bring one of the first 'stem cell' therapies to market in the next 3 to 5 years.
I think it's a well managed company and should out perform the market.
New cardiac technologies to take off
NeoStem is projected to have their first treatment commercialized in 2017.
Allah peanut butter sandwiches;)~
rock solid on the current market pullback. Watch this fly once it gets the chance
Most of the medical profession, maybe not Wall Street, recognizes we've entered a new age in cancer and cardiac care. Thanks to stem cell and genetics research, we're moving from cutting to perhaps curing, or in the very least, offering patients less invasive procedures that may very well help extend their lives.
Highly undervalued considering the amount of potential it has. I'm not religious but you can't bet against a company backed by the Pope either :)
I'm in NY and I know this company. Expect some future stock dilution or debt issues if it stays independent but I expect it will be acquired at some point.
Stem cell expertise.
This is a high risk / high reward extreme speculation, on my part.This is based on current momentum.
Should've put this at five years, long term stem cell research play
If you can wait three years and have the stomach to get into the stem cell sector, then this stock is probably going to make you a pretty wealthy investor
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions